Sustained drug delivery of capecitabine using natural (bee wax) and synthetic polymer (PLGA)

Abstract

Sustained/controlled release is designed to release a drug at a predetermined rate in which a constant drug concentration maintained for a specific period with minimal side effects and drug consumption. This can be achieved via various formulations, including liposomes, solid lipid microspheres and drug–polymer conjugates. The role of polymer in drug delivery is to provide weight, consistency and volume for the right and proper administration of the drug. It provides synergistic functions, stability, drug release, targeting, enhancing its bioavailability and patient acceptability. Beeswax, a natural polymer is considered as a base biomaterial for preparation of microspheres and loading with Capecitabine, an anti–cancer drug for drug delivery. The Beeswax microspheres via coacervation and phase separation method were in the mean diameter of 3441nm and SEM micrograph reveals the distribution of beeswax microsphere in Poly Lactic Glycolic Acid (PLGA) medium uniformly. The interaction between beeswax, PLGA and drug were interpreted by FTIR and confirming the drug–polymer interactions. In–vitro drug release of Beeswax microspheres confirms a linear behaviour with 26% of the drug released in the dissolution medium at pH 6.8. The cell culture confirms the good biocompatibility of beeswax microspheres concluding the beeswax could be used to fabricate the drug delivery and targeting vehicles in cancer therapy.

Keywords: beeswax, PLGA, capecitabine, microspheres, in–vitro drug release and cell culture

Introduction

Drug delivery is a platform for formulating a system for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect with a minimal dosage. It involves site specific–targeting within the body or involving facilitating systemic pharmocokinetics with both quantity and duration of the drug at the site of delivery. It can be functionalized via a drug’s chemical formulation, but it may also involve medical devices or drug–device combination products. This system provides the plasma and tissue drug levels in the body and preventing any damage to the healthy tissue via the drug toxicity. Smart polymers used in the fabrication of drug delivery systems. These polymers have the ability to act on external stimuli like light, pressure, temperature, pH, electric field, etc., Polymers considered in designing drug delivery system should provide a considerable weight, solution consistency and volume for the proper administration of the drug and in addition, they are multi–tasking offering stability of the drug at the site of injury, drug release, targeting to the specific part of organs or tissues, enhanced bioavailability and patient acceptability. Polymers are classified based on the following groups: source (Natural, semi–synthetic, synthetic); structure of polymer (Linear, Branched–chain, Crosslinked or Network polymers); type of polymerization (Addition, condensation polymers); molecular forces (Elastomers, Fibres, Thermoplastic, Thermosetting); Chain–growth polymerization (Free radical governed); degradability (biodegradable, non–biodegradable). Both natural and synthetic polymers are used in drug delivery design and targeting. Natural polymers are usually large molecular weights from a natural source such as plants, micro–organisms and animals. Natural polymers are capable to tailor its properties due to low toxicity, renewability, flexibility to modification, biodegradability and low cost. Natural polymers usually made up of polysaccharides or proteins are hydrophilic, enzymatically degradable. Polymers like Beeswax are hydrophobic in nature which is inert and biodegradable. It has good hemocompatibility and high interaction with living cells making them compatible and suitable biomaterials for long systemic circulation and targeting. Most of the natural polymers are generally regarded as a safe zone for oral consumption and degradable via a metabolic pathway in the human body.

Bio–synthesis of beeswax

Beeswax is produced by the work bee Apis mellifera L. Around the world, beeswax was produced from A.cerana and A. florea as well as other honeybee species. Formation and secretion of wax take place at gland complexes consisting of three cell types: epithelial cells, oenocytes and adipocytes, which act synergistically to secrete wax. It is a constant process and starts in a week old honey bee workers, goes a peak after 2weeks of age and thereafter decreases.

Composition of beeswax

Beeswax is a unique complex mixture of both saturated and unsaturated linear and complex monoesters, hydrocarbons, free fatty acids, free fatty alcohols and other minor exogenous substances. It is reported that a normal bee wax consists of a total content of 27 to 40% monoesters, 9 to 23% hydroxy–monoesters, 7 to 16% diesters, 3.9% hydroxy–diesters, 11 to 28% hydrocarbons, 1 to 18% saturated, unbranched free fatty acids, 4 to 8% of other substances and less than 0.3% free fatty alcohols from different bees species.
Properties of beeswax

Melting range—between 62°C and 65°C Specific gravity (D,0)—about 0.96, Solubility—Insoluble in water, Sparingly soluble in alcohol. Very soluble in chloroform and ether, Purity Acid value—not less than 17 and not more than 24 (mg KOH/g beeswax) Saponification value—87–104 (mg KOH/g beeswax) Peroxide value (mM H₂O₂/1000g beeswax): not more than 5 Glycerol and other polyols: not more than 0.5% (as glycerol) Ceresin, paraffin and certain other waxes: absent. The synthetic polymer has more advantages and their physicochemical properties tailored for designing drug delivery system. Especially, synthetic water–soluble polymers modify its physical properties of aqueous systems in the form of gelation, thickening or emulsification/ stabilization when it dissolves in water or aqueous medium. These polymers usually have repeating units or blocks of units (e.g. PEG); the polymer chains contain hydrophilic groups that are substituents or are incorporated into the backbone. The hydrophilic groups may be non–ionic, anionic, cationic or amphoteric.5

Poly (lactic–co–glycolic acid)

PLGA or Poly (lactic–co–glycolic acid) is a copolymer, and an approved polymer by Food and Drug Administration (FDA) for developing therapeutic and medical devices due to its outstanding biodegradability and biocompatibility with biological systems. It is made by a process of ring–opening copolymerization of two different monomers, the cyclic dimers (1,4‒dioxane‒2,5‒diones) of glycolic acid and lactic acid. PLGA is a successful biodegradable polymer. It undergoes hydrolysis in the body to produce the original monomers, lactic acid and glycolic acid, a metabolite which is excreted easily in the body via various metabolic pathways. These monomers have very minimal systemic toxicity for constructing drug delivery devices or biomaterial scaffold for tissue engineering applications Figure 1.

Figure 1 crude beeswax.

Physical properties


Model drug

Capecitabine is a prodrug of 5‒fluorouracil which is inactive, and this prodrug converted into an active drug via enzymatic conversion occurring only in tumour tissue.6 It is an oral prodrug of 5‒FU which passes as a native formulation through the gut wall and then converted into 5'dFCR following changed to 5'-deoxy-5-fluorouridine (5'dFUR) in the liver via enzymatic reaction with carboxylesterase and cytidine deaminase respectively. 5'dFUR is finally then converted to 5‒FU via thymidine phosphorylase or uridine phosphorylase.6,7 The main mechanism of 5–FU activation is conversion to fluorodeoxyuridine monophosphate (FdUMP) which inhibits the enzyme thymidylate synthase (TYMS), a component of the folate‒homocysteine cycle and purine and pyrimidine synthesis Table 1. This paper deals the synthesis of beeswax microspheres by using melt dispersion method and to evaluate the drug loading capacity of the microspheres by using a model anti‒cancer drug capecitabine and its drug release studies and to coat the PLGA polymer incorporated with the model drug, on the outer surface of the beeswax microspheres and its characterization studies Figure 2.

Table 1 pharmacokinetic data

<table>
<thead>
<tr>
<th>Bioavailability</th>
<th>Extensive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein binding</td>
<td>&lt; 60%</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Hepatic, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil</td>
</tr>
<tr>
<td>Biological half– life</td>
<td>38–45 minutes</td>
</tr>
<tr>
<td>Excretion</td>
<td>Renal (95.5%), faecal (2.6%)</td>
</tr>
</tbody>
</table>

Figure 2 Structure of PLGA. where, X = no of units of lactic acid and Y = no of units of glycolic acid.

Materials and methods

Collection of beeswax and PLGA

Crude beeswax (yellow) was collected from Dindigul, Tamil nadu, India. It was further melted and filtered to remove the impurities. PLGA (50:50) was purchased from Sigma Aldrich.

Synthesis of beeswax microsphere

1.5grams of Beeswax was melted separately in a hot air oven at a temperature of 60±1°C. Model Drug (0.13gm) was added to the melted condition of wax and stirred and dispersed to obtain a homogeneous melt. This mixture was poured into 33ml of Ammonia buffer solution for minimizing the solubility of the drug at pH 10.9. While adding the ammonia buffer solution, the wax is heated and melted just higher than 65±1°C. Tween 80 (1.8% w/w) was also added to the mixture. This mixture was well stirred at 900RPM using a stirrer (RQ‒127A) fitted with a 4‒blade impeller of 53mm diameter. During mixing

process, spherical particles containing drug and wax are produced due to the dispersion of molten wax in the aqueous medium. The mixture was stirred continuously at 900rpm at a higher temperature (65°C) of the melting point of wax for 4min. The temperature of the mixture in the beakers was cooled rapidly to 10°C by the addition of cold water Figure 3. The resultant solid spheres were collected by filtration were extensively washed with water to remove drug adsorbed on the surface and surfactant residues. Air drying was carried out at room temperature for 48h to get free-flowing solid microspheres.

Preparation of PLGA–drug solution by phase separation method

Coacervation is a process preparing a microsized biodegradable polymer via liquid–liquid phase separation method. In this method, it yields two liquid phases via phase separation namely the polymer containing coacervate phase and the supernatant phase depleted in the polymer. The drug which is dispersed/dissolved in the polymer solution is coated by the coacervate. In this study, PLGA Polymer mixed with a solvent (800µl) in appropriate ratios to form a solution. The drug capecitabine (10mg) was dissolved in water (1ml) and dispersed in the polymer solution (water–in–oil emulsion). The gradual addition of organic medium to the polymer–drug–solvent solution phase extracts the polymer solvent resulting in phase separation of the polymer by forming a soft coacervate of drug–containing droplets. The size of the droplets was controlled by varying stirring rate and temperature of the system. After vortex at 1000rpm and ultrasonication for 7000rpm, the resultant solution could air dry at room temperature for 24hrs for solvent evaporation. For next 24hrs, the solution kept in refrigeration to keep that in a liquid phase. Already synthesized drug loaded beeswax microspheres were mixed with this solution which made dispersion. In-room temperature PLGA obtained gel–like consistency Figure 4. It has the ability of up taking water and gets swollen. Thus, it will act as a hydrogel at the site of injury and swells in a physiological environment.

Characterization studies

The synthesized micro-sized polymer was characterized by FTIR (Model Name FT/IR–6300 type), UV visible spectrophotometer (UV 1800–Shimadzu), SEM (Zeiss) and PSA.

In vitro drug release

In vitro release of Capecitabine from microspheres was studied using a USP dissolution apparatus (Pharma test). Phosphate buffer solutions of pH 6.8 were used as dissolution medium, their pH was adjusted by adding HCl or NaOH solutions Table 2. 100mg of microspheres were added in cellulose dialysis tube containing 4ml of dissolution medium and tied to the paddle. The paddle was rotated at 100rpm in 500ml of phosphate buffer solution of pH 6.8 at 37°C. A 2ml sample was withdrawn at predetermined time intervals i.e. 0, 1, 2, 3, 4, 5, 6, 8 and 24h and an equal volume of fresh dissolution medium, which was prewarmed at 37°C, was replaced. Collected samples were suitably diluted and then analysed for Capecitabine contents by measuring the absorbance at 283nm using an ultraviolet spectrophotometer (1800–Shimadzu UV–spectrophotometer). The concentration of Capecitabine in test samples was calculated using calibration curve.

Table 2 show different stretches of bonds shown at different peaks

<table>
<thead>
<tr>
<th>Peaks(Cm⁻¹)</th>
<th>Functional groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>2918–2850</td>
<td>C– H stretch</td>
</tr>
<tr>
<td>1736</td>
<td>C=O stretch</td>
</tr>
<tr>
<td>1173</td>
<td>Estates</td>
</tr>
<tr>
<td>1750–1760</td>
<td>Carbonyl Group</td>
</tr>
<tr>
<td>1200–1000</td>
<td>C–OH</td>
</tr>
<tr>
<td>1160–1083</td>
<td>Ether group</td>
</tr>
<tr>
<td>1408</td>
<td>Aromatic stretch</td>
</tr>
</tbody>
</table>

Figure 4 Preparation of drug delivery vehicles.
Cell passaging

In this study in vitro biocompatibility of the beeswax, microspheres were carried out on Human Umbilical Vein Endothelial Cells (HUVEC) EA. hy 926. Confluent grown cell culture was bought as a gift sample from cell culture lab, Anna University MIT campus, Chennai. Confluent grown cells were resuspended in 1ml of 1X PBS and mixed gently. This mixture was added with 1ml of Trypsin Phosphate Versene Glucose 1X. Trypsin was pipetting out and the flask was kept in an incubator for 2minutes and then checked for detachment of cells. After that 1ml of cell culture media was added and mixed well.

Cell counting

Several cells present in cell culture flask was calculated using Neubauer chamber. 10µl of cells and 10µl Trypan blue dye was added and mixed well. 10µl of this sample mixture was taken and poured under the coverslips and chamber. This was viewed under microscope and cells were counted using the formula given below.

No of cells in 1ml=Total no of cells in 16 small squares *(dilution factor)*10^4

Result and discussion

The beeswax microspheres were synthesized. The size of the spheres was trying to be reduced by increasing the stirring rpm and the time of stirring was extended up to 30minutes.

Particle size analyzer

Particle size analysis was performed by dynamic light scattering (DLS) with a Malvern Zetasizer 3000HSA (Malvern Instruments, UK). Figure 5A & 5B shows particle size distribution of beeswax microspheres. DLS yields the mean diameter and the polydispersity index (PI) which is a measure of the width of the size distribution. The mean diameter and PI values were obtained at an angle of 90° in 10mm diameter cells at 25°C. Prior to the measurements, all samples were diluted with double distilled water to produce a suitable scattering intensity. The synthesized microspheres were in the mean diameter of 3441nm or 34µm.

Scanning electron microscope

Surface morphology of the microspheres was observed on the scanning electron microscope (Zeiss–Model S3). From the Figure 6, the distribution of beeswax microsphere in PLGA was observed uniformly. The spherical shape of beeswax microspheres were easily visualised. At the elevated temperature of above 35°C, the PLGA with the appearance of semi-solid gel phase can be easily observed with beeswax microspheres.

Fourier transform infra-red spectroscopy

Drug–polymer interactions were studied by FTIR spectroscopy (Model Name FT/IR–6300 type). The spectra were recorded for the pure drug, drug–loaded microspheres and PLGA coated microspheres using FTIR. Samples were prepared in KBr disks (2mg sample in 200mg KBr). The scanning range was 400–4000cm⁻¹ and the resolution was 2cm⁻¹. The results of FTIR analysis of this study show different stretches of bonds shown at different peaks. Figure 7 shows peaks near 2918–2850cm⁻¹ which corresponds to C‒H stretch, peaks near 1736cm⁻¹ corresponds to C=O stretch, peaks near 1173cm⁻¹ corresponds to a functional group of esters. In Figure 8, 1750–1760cm⁻¹ corresponds to a carbonyl group. 1200–1000cm⁻¹ region corresponds to C–OH side groups and peaks near 1421cm⁻¹ corresponds to C=C stretch, peaks near 1160–1083cm⁻¹ corresponds to ether group, peaks near 1408cm⁻¹ corresponds to aromatic stretch. Thus, we could conclude that the missing functional groups in Figure 9 may participate in the bonding of beeswax and PLGA polymers. From the release studies, it was observed that there was an initial burst of a drug in the solution due to the Swelling of PLGA. In the first 2h, at 6.8pH, 6% of the drug release was observed. But after 2hours the release of a drug was in a slow rate. The microspheres showed a sustained release pattern at pH 6.8 (Figure 10). In 24hours the drug release was in a linear manner and approximately 26% of the drug was released in the dissolution medium of pH 6.8.

Biocompatibility assay for beeswax

The cell line Human Umbilical Vein Endothelial Cells (HUVEC) EA.hy926 were seeded in a 24 well plate as a triplicate at 3 various concentrations from lower to higher. it was further incubated for 24hrs in 5% CO₂ incubator. The results showed that even in higher concentration, the cells were alive (Figure 11).
Sustained drug delivery of capecitabine using natural (bee wax) and synthetic polymer (PLGA)

Discussion

Recently, natural polymers are played a major role in the development of drug delivery system and other biomedical devices. Bee wax is one of the most abundant natural polymers under the category of wax and prepared from honeycomb as a natural source and this wax itself has potential pharmacological activities such as lowering cholesterol and pain-relieving activity. This material used as an anti-inflammatory agent for swelling, ulcers and diarrhoea. Apart from the medicinal application, it is used in food processing as a stiffening agent and a thickener and emulsifier. Additionally, it is a fragrance material in soap and perfume processing. It is declared that bee wax is a safe material for the medical and pharmaceutical application.\textsuperscript{16,17} Bee wax chemically composed of fatty acids esters and numerous long chain alcohols and edible in nature and no toxicity like plant waxes. The important components of bee wax are monoesters, hydrocarbons, diesters and free fatty acids. The physical properties of bee wax are exceptional and solid at cold temperature and tailoring its melting properties with temperature and it can be used to fabricate/formulate drug delivery vehicles such microspheres/nanoparticles for sustained and controlled drug delivery system.\textsuperscript{18} Bee wax microspheres can be used as a potential drug delivery of nateglinide, an antidiabetic drug and other drugs. In this work, bee wax microspheres as drug delivery vehicles prepared via the chemical method and the size of the microspheres can be controlled by numerous process parameters such as agitation speed, wax/solvent ratio, agitation time and temperature.\textsuperscript{19} The coating of Bee wax microspheres with PLGA could increase its biocompatible

and drug loading performance for the controlled delivery system. In the present investigation, the size of the nanoparticle was obtained as 3441nm when compared with the values obtained as 4000nm. From this result, it was observed that the size nanoparticle was found to be comparable with the other research work established Figure 12. The SEM micrograph reveals the distribution of bee wax microspheres in the PLGA medium uniformly. The chemical processing of bee wax yields the formation of spherical micro particles having good surface area and good contact with the biological medium. FTIR confirms no chemical interaction with drug and biopolymers bee wax and PLGA. The methodology of drug release in the waxy material is controlled by erosion/diffusion of drugs. In this study\textsuperscript{19,21} drug release from the waxy formulations exhibited zero order kinetics. Due to the erosion of waxy material and diffusion of drug through the beeswax, a constant release rate was observed. From cell culture studies, it was concluded that the beeswax microspheres were biocompatible for the construction of controlled drug delivery system.\textsuperscript{22}

**Figure 12** Cell cultures studies on beeswax microspheres like Control cell line. Cell line with beeswax.

**Conclusion**

The beeswax microspheres loaded with the drug were formed using melt dispersion technique. These BW microspheres construct the inner core of the drug delivery system. These BW microspheres were dispersed in the drug incorporated PLGA. This formulation played as a sustained drug delivery system for anti-cancer drugs such as capecitabine which was only suitable for oral drug administration. From SEM analysis it concludes that the beeswax microspheres were dispersed in the PLGA and formed a gel–like substance at room temperature. By focusing the in–vitro drug release study, it was accounted that the release was in a slow rate and approximately 25% of the drug from the formulation was released in 24hours, concluding the Bee Wax microspheres can be a potential drug delivery vehicles and drug targeting in cancer therapy.

**Acknowledgments**

None.

**Conflict of interest**

Author declares that there is no conflict of interest.

**References**


